PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportsrenal cell carcinoma
MeSH D002292 - renal cell carcinoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D007680:Kidney neoplasms
18 Companies
5 Drugs
$
Success rate
D000230:Adenocarcinoma
24 Companies
3 Drugs
$
Success rate
D002292: 
Renal cell carcinoma
55 Companies
25 Drugs
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaMedroxyprogesterone Medroxyprogesterone  2004-10-27   
Sorafenib Sorafenib  2020-11-12   
Sunitinib Sunitinib  2021-11-30   
Pazopanib Pazopanib  2023-10-19   
MylanBevacizumab Abevmy  2021-04-21   
Bevacizumab Lextemy     
Sorafenib Sorafenib  2020-09-10   
Sunitinib Sunitinib  2021-12-06   
XiromedMedroxyprogesterone Medroxyprogesterone  2018-10-12   
RocheBevacizumab Avastin  2005-01-12 $1,987.484 M Q4/22-Q3/23 
Ribavirin, Peginterferon alfa-2a Pegasys Copegus  2004-06-04   
Interferon alfa-2a Roferon-A  1986-06-04   
CiplaMedroxyprogesterone Medroxyprogesterone  2019-01-25   
SandozMedroxyprogesterone Medroxyprogesterone  2009-05-20   
NovartisEverolimus Afinitor  2009-08-02 $789 M Q2/20-Q2/23 
Pazopanib Votrient 2023-10-19 2009-10-19 $545 M Q2/20-Q2/23 
WyethMedroxyprogesterone, Estrogens, conjugated Premphase (premarin;cycrin )  1994-12-30   
Medroxyprogesterone, Estrogens, conjugated Prempro  1995-11-17   
Merck Sharp & DohmeInterferon alfa-2b Intron A  1986-06-04   
Interferon alfa-2b IntronA  2000-03-09   
Pembrolizumab Keytruda  2015-07-17 $26,163 M Q2/23-Q1/24 
Peginterferon alfa-2b PegIntron  2001-01-19   
Ribavirin, Peginterferon alfa-2b PegIntron/ Rebetol Combo Pack  2008-06-13   
Interferon alfa-2b Viraferon  2000-03-09   
Peginterferon alfa-2b ViraferonPeg  2000-05-28   
BayerSorafenib Nexavar 2023-02-11 2005-12-20   
1
2
3
4
5
6
>
Clinical Trials
Historical Success Rate
Phase 1
71%
119/168
Phase 2
25%
47/190
Phase 3
59%
46/78
Approved: 27Overall Success rate: 10%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
Medroxyprogesterone,
Medroxyprogesterone acetate
Mylan
Bevacizumab
Roche
Bevacizumab,
Ribavirin,
Peginterferon alfa-2a,
Interferon alfa-2a,
Benzocaine,
Albumin,
Antithrombin iii,
Tiragolumab,
Alfacalcidol,
Albinterferon alfa-2b,
EGANELISIB,
SIMLUKAFUSP ALFA,
Ro7515629
Novartis
Everolimus,
Pazopanib,
Benzocaine,
Antithrombin iii,
Dactolisib,
Tozadenant,
Spartalizumab,
Gevokizumab,
Dovitinib,
Sodium chloride,
Sodium lactate,
Albinterferon alfa-2b,
Microcrystalline cellulose,
Retinol,
Nir178,
Hkt288,
Kfa115,
Dff332
Merck Sharp & Dohme
Pembrolizumab,
Ribavirin,
Interferon alfa-2b,
Peginterferon alfa-2b,
Epacadostat,
Aglatimagene besadenovec,
Tivantinib,
Alfacalcidol,
Tryptophan,
Sodium chloride,
Quavonlimab,
Vibostolimab,
Retinol,
Mk-4280,
Ngm707,
Ngm438,
Gb1275,
Mrx0518
Bayer
Sorafenib,
Transplatin,
Radium ra-223,
Regramostim,
Molgramostim,
ORTATAXEL
Pfizer
Bevacizumab,
Axitinib,
Temsirolimus,
Sunitinib,
Medroxyprogesterone,
Sunitinib malate,
Medroxyprogesterone acetate,
Selenomethionine se-75,
Utomilumab,
Sasanlimab,
Aglatimagene besadenovec,
Agatolimod,
Girentuximab,
Terfenadine,
Tryptophan,
Sodium chloride,
Sodium lactate,
Microcrystalline cellulose
Sun Pharmaceutical Industries
Medroxyprogesterone,
Medroxyprogesterone acetate
Bristol Myers Squibb
Nivolumab,
Thalidomide,
Ipilimumab,
Benzocaine,
Transplatin,
Bempegaldesleukin,
Cilmostim,
Entinostat,
Regramostim,
Vorhyaluronidase alfa,
SOTIGALIMAB,
VARLILUMAB,
Sodium lactate,
CABIRALIZUMAB,
Microcrystalline cellulose
1
2
3
4
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use